

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

| | | | |
|--|---|--|---|
| 1. Name and Address of Reporting Person* <u>Majors Cary L</u> (Last) (First) (Middle) <u>C/O 70 SIR JOHN ROGERSON'S QUAY</u> (Street) <u>DUBLIN L2 2</u> (City) (State) (Zip) | 2. Date of Event Requiring Statement (Month/Day/Year) <u>05/07/2019</u> | 3. Issuer Name and Ticker or Trading Symbol <u>STERIS plc [STE]</u> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>VP, N America Com Operations</u> | 5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person |
|--|---|--|---|

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|
| <u>Ordinary Shares</u> | <u>18,020⁽¹⁾</u> | <u>D</u> | |

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---|--|-------------------|---|--|--|---|
| | Date Exercisable | Expiration Date | | | | |
| <u>Employee Stock Option (right to buy)</u> | <u>(2)</u> | <u>05/28/2025</u> | <u>Ordinary Shares</u> | <u>2,250</u> | <u>66.15</u> | <u>D</u> |
| <u>Employee Stock Option (right to buy)</u> | <u>(3)</u> | <u>06/01/2026</u> | <u>Ordinary Shares</u> | <u>6,000</u> | <u>69.72</u> | <u>D</u> |
| <u>Employee Stock Option (right to buy)</u> | <u>(4)</u> | <u>05/31/2028</u> | <u>Ordinary Shares</u> | <u>14,932</u> | <u>114.22</u> | <u>D</u> |

Explanation of Responses:

1. 18,020 of these shares are restricted. The restrictions on the ordinary shares lapse as follows: 2,000 on May 28, 2019; 1,500 on May 28, 2019; 3,000 on October 1, 2019; 2,500 on June 1, 2020; 6,500 on May 31, 2021 and 2,520 on May 31, 2022.
2. This option becomes exercisable as follows: 2,250 on May 28, 2016; 2,250 on May 30, 2017; 2,250 on May 29, 2018 and 2,250 on May 28, 2019. This option was received under the Scheme in exchange for an option to purchase 9,000 STERIS ordinary shares for \$66.15 per share, subject to the same terms and conditions as the original Old STERIS stock option.
3. This option becomes exercisable as follows: 3,000 on June 1, 2017; 3,000 on June 1, 2018; 3,000 on June 3, 2019 and 3,000 on June 1, 2020. This option was received under the Scheme in exchange for an option to purchase 12,000 STERIS ordinary shares for \$69.72 per share, subject to the same terms and conditions as the original Old STERIS stock option.
4. This option becomes exercisable as follows: 3,733 on May 31, 2019; 3,733 on June 1, 2020; 3,733 on June 1, 2021 and 3,733 on May 31, 2022. This option was received under the Scheme in exchange for an option to purchase 14,932 STERIS ordinary shares for \$114.22 per share, subject to the same terms and conditions as the original Old STERIS stock option.

Remarks:

/s/ Ronald E. Snyder,

Authorized Representative
under Power of Attorney

05/16/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

RE: STERIS plc
1933 Act and 1934 Act Filings
Authorized Representatives
Ladies and Gentlemen:

The above Company, a public limited company organized under the laws of Ireland, is or will be the issuer of securities registered under Section 12 of the Securities Exchange Act of 1934. The undersigned confirms, as of the date appearing opposite his/her signature, that each of the "Authorized Representatives" named below is authorized on his/her behalf to sign such statements (on Form 3, Form 4, Form 5, Form 144, Schedule 13G, Form ID (if necessary) or otherwise, collectively, "Forms") with respect to securities of the Company (the "Securities"), and to submit to the Securities and Exchange Commission such Forms (including reports, notices, and other statements) with respect to the Securities, as are required by the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934 as amended (collectively, the "Acts"). The undersigned also confirms the authority of each of the Authorized Representatives to do and perform, on his/her behalf, any and all acts and things with respect to the Securities requisite or necessary to assure compliance by the undersigned with the filing requirements of the Acts.

This authority revokes all prior authorities with respect to the Securities previously executed by the undersigned including but not limited to any such authorities filed with or given to the Commission by the undersigned. This authority contained herein shall remain in full force and effect until the undersigned is no longer required to file Forms with respect to the undersigned's holdings of and transactions in the Securities, unless earlier revoked by the undersigned in a signed writing delivered to the Authorized Representatives.

Authorized Representatives

Patricia Comai
Judith A. Hunter
Julia Kipnis
Rebecca A. Nichols
Ronald E. Snyder
Michael J. Tokich
J. Adam Zangerle

The undersigned acknowledges that the foregoing Authorized Representatives, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with the Acts. Additionally, although pursuant to this authority, the Authorized Representatives will use commercially reasonable efforts to timely and accurately file the required Forms on behalf of the undersigned, the Authorized Representatives do not represent or warrant that they will be able to in all cases timely and accurately file such Forms on behalf of the undersigned due to various factors and the undersigned and the Authorized Representatives' need to rely on others for information, including the undersigned and brokers of the undersigned.

Dated: May 7, 2019

By: /s/ Cary L. Majors
Signature

Printed Name
Cary L. Majors